癌症中的类放射性对象 治疗学:激进分子和对抗分子
Berthold A Nock1, Panagiotis Kanellopoulos1, Lieke Joosten2
1Molecular Radiopharmacy, INRaSTES, NCSR "Demokritos", 15310 Athens, Greece.
Pharmaceuticals (Basel, Switzerland)
|May 27, 2023
概括
与激动剂相比,向癌症受体的放射性标记抗剂提供了改善的瘤积累和更快的清除. 这种转变提高了向癌症治疗药物的安全性和有效性.
科学领域:
- 核医学和分子成像学.
- 瘤学和向癌症治疗.
- 放射性药物的开发. 放射性药物的开发.
背景情况:
- 索马托斯坦素受体亚型2 (SST2R) 放射性连接体在癌症治疗中的临床成功.
- 在各种癌症类型中利用受体过度表达用于向治疗.
- 在放射性药物设计中,新兴趋势是采用受体对抗剂而不是激动剂.
研究的目的:
- 审查针对癌症治疗的对抗剂基放射性药物的进展.
- 突出新型放射连接体的临床结果和潜力.
- 讨论使用这些药物进行个性化癌症治疗的挑战和机会.
主要方法:
- 对针对各种癌症受体的对抗性放射性对象的最新文献的综述.
- 对索马托斯塔丁,庞贝辛,胃素和埃森丁类型的临床前和临床数据的分析.
- 专注于受体对抗剂的有效性,瘤积累和背景清除.
主要成果:
- 作为SST2R抗剂的放射性对象,其瘤向性优越,清除速度比激动剂更快.
- 与线性BBN相比,贝素 (BBN) 类抗剂提供了更好的安全性和有效性.
- 素和素对手放射性连体的进展显示出有前途的临床结果.
结论:
- 基于抗体的放射性药物代表了癌症治疗学中的显著范式转变.
- 这些药物提供了增强的瘤向性,改善的安全性,以及个性化癌症治疗的潜力.
- 进一步的开发有望为更有效和量身定制的瘤疗法提供希望.
相关概念视频
Drug-Receptor Interaction: Agonist
2.6K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drug-Receptor Interactions
5.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.4K
Drug-Receptor Interaction: Antagonist
3.1K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
3.1K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


